| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
N-Oleoyl-L-serine targets the endocannabinoid system, playing an essential role in the maintenance of normal bone mass via signaling through the CB2 receptor. It functions as a lipid regulator of bone remodeling, stimulating osteoclast apoptosis. By promoting bone formation and inhibiting bone resorption, it modulates the balance of bone metabolism.
|
|---|---|
| ln Vitro |
In vitro, N-Oleoyl-L-serine stimulates bone formation and inhibits bone resorption in cell-based models. It promotes the apoptosis of osteoclasts, which are the cells responsible for bone resorption. This activity makes it a promising candidate for the study of osteoporosis and other bone-related disorders.
|
| ln Vivo |
N-Oleoyl-L-serine has been reported to stimulate bone formation and inhibit bone resorption in vivo. Its modulatory bioactivity has implications for the treatment of osteoporosis, neurodegenerative disorders, and metabolic regulation. By modulating the endocannabinoid system, it influences bone mass maintenance.
|
| Enzyme Assay |
The activity of N-Oleoyl-L-serine is typically studied using cell-based functional assays. For example, osteoblast and osteoclast cultures are treated with the compound to measure its effects on cell proliferation, differentiation, and apoptosis. Receptor binding assays can be used to confirm its interaction with the CB2 receptor.
|
| Cell Assay |
Cellular assays for N-Oleoyl-L-serine involve treating bone cells (e.g., osteoblasts, osteoclasts, and their precursors) with the compound. Bone formation is assessed by measuring alkaline phosphatase activity and mineralization. Bone resorption is assessed by measuring the release of calcium or the activity of tartrate-resistant acid phosphatase (TRAP).
|
| Animal Protocol |
In vivo studies of N-Oleoyl-L-serine are conducted in animal models of osteoporosis, such as ovariectomized rodents. The compound is administered via intraperitoneal (i.p.) injection or oral gavage. Bone mineral density is measured using DEXA scans, and bone turnover markers are assessed in serum. Histomorphometric analysis of bone tissue is performed to evaluate bone formation and resorption parameters.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Oleoyl-L-serine are not extensively characterized in publicly available sources. As an endogenous lipid, it is expected to be metabolized through lipid metabolic pathways. It is typically formulated in DMSO or other organic solvents for in vitro studies.
|
| Toxicity/Toxicokinetics |
N-Oleoyl-L-serine is intended for research use only and is not for therapeutic or diagnostic use in humans. As an endogenous compound, its toxicological profile is expected to be favorable at physiological concentrations. Standard laboratory safety practices should be followed when handling this compound.
|
| References |
[1]. Reem Smoum, et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17710-5.
|
| Additional Infomation |
N-Oleoyl-L-serine is a derivative of L-serine, formed by the condensation of the carboxyl group of oleic acid and the amino group of L-serine. It plays a role in maintaining bone density and is also a metabolite in mice. It is an L-serine derivative belonging to the N-(fatty acyl)-L-α-amino acid family. Its function is related to oleic acid. It is the conjugate acid of N-oleoyl-L-serine. There are reports and relevant data regarding the presence of N-oleoyl-L-serine in Brassica napus.
N-Oleoyl-L-serine is an endogenous lipid regulator of bone remodeling that stimulates osteoclast apoptosis. It is used in the study of bioactive N-acyl amides and has potential applications in anti-osteoporotic drug discovery. It is a valuable research tool for understanding the role of the endocannabinoid system in bone metabolism. |
| Molecular Formula |
C21H39NO4
|
|---|---|
| Molecular Weight |
369.54
|
| Exact Mass |
369.287
|
| CAS # |
107743-37-3
|
| PubChem CID |
44190514
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
571.9±50.0 °C at 760 mmHg
|
| Flash Point |
299.7±30.1 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.489
|
| LogP |
6.09
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
26
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(N[C@H](C(O)=O)CO)=O
|
| InChi Key |
MBDKGXAMSZIDKF-VJIACCKLSA-N
|
| InChi Code |
InChI=1S/C21H39NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(24)22-19(18-23)21(25)26/h9-10,19,23H,2-8,11-18H2,1H3,(H,22,24)(H,25,26)/b10-9-/t19-/m0/s1
|
| Chemical Name |
(2S)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7061 mL | 13.5303 mL | 27.0607 mL | |
| 5 mM | 0.5412 mL | 2.7061 mL | 5.4121 mL | |
| 10 mM | 0.2706 mL | 1.3530 mL | 2.7061 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
